Business
Press Release Mar 05 2024
Strides Pharma Science Limited has informed the Exchange regarding a press release dated March 05, 2024, titled "Strides receives USFDA approval for Gabapentin Tablets USP, 600 mg and 800 mg".
About this update from Strides Pharma Science Ltd
Strides Pharma Science Limited has informed the Exchange regarding a press release dated March 05, 2024, titled "Strides receives USFDA approval for Gabapentin Tablets USP, 600 mg and 800 mg". View Attachment
View stock analysis, news, and events for Strides Pharma Science Ltd